Tamoxifen usage correlates with increased risk of Parkinson’s disease in older women with breast cancer: a case–control study in Taiwan
- 1 October 2017
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Pharmacology
- Vol. 74 (1), 99-107
- https://doi.org/10.1007/s00228-017-2341-0
Abstract
Little is known about the association between tamoxifen usage and risk of Parkinson’s disease in women with breast cancer. The present study aimed to evaluate the association between tamoxifen usage and Parkinson’s disease in older women with breast cancer in Taiwan.Keywords
This publication has 82 references indexed in Scilit:
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trialThe Lancet, 2013
- Sleep and non-motor symptoms in Parkinson’s diseaseJournal of Neural Transmission, 2013
- Meta‐analysis of early nonmotor features and risk factors for Parkinson diseaseAnnals of Neurology, 2012
- Polypharmacy increases the risk of Parkinson's disease in older people in Taiwan: A population‐based studyPsychogeriatrics, 2011
- Polypharmacy Correlates With Increased Risk for Hip Fracture in the ElderlyMedicine, 2010
- Accuracy of clinical diagnosis in tremulous parkinsonian patients: a blinded video studyJournal of Neurology, Neurosurgery & Psychiatry, 2010
- Risk of Parkinson's disease after tamoxifen treatmentBMC Neurology, 2010
- Reproductive factors, exogenous estrogen use, and risk of Parkinson's diseaseMovement Disorders, 2009
- Raloxifene blocks estradiol induction of the serotonin transporter and 5-hydroxytryptamine2A receptor in female rat brainNeuroscience Letters, 2007
- Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsThe Lancet, 2005